Cross-Sector entity
Brookings Metro is the most frequent co-covered peer, appearing in 3 of the 6 tracked stories. Across a 123-day span, the pace is roughly 0.3 stories per week. The busiest single day carried 3. Coverage clusters in clinical-trial, which accounts for 2 of those 6, with the remainder spread across 3 other categories.
6 verified stories tracked
Last mentioned: Jul 6, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 33 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Brookings Metro is the most frequent co-covered peer, appearing in 3 of the 6 tracked stories. Across a 123-day span, the pace is roughly 0.3 stories per week. The busiest single day carried 3. Coverage clusters in clinical-trial, which accounts for 2 of those 6, with the remainder spread across 3 other categories. The tracked stories average 5.8 original sources each. 0% of these stories carry negative sentiment. Johns Hopkins University appears in 6 tracked Cross-Sector stories published from March 6, 2026 through July 6, 2026.
Computed from the 6 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Johns Hopkins University. Shared-story counts are live from our verified record — not editorial picks.
Gallup-Brookings Report
Data reveals rising usage but significant friction in scaling AI across legacy organizations.
Gallup/Brookings Report
Research identifies structural 'speed bumps' hindering the next phase of AI adoption.
The Implementation Wall
Gallup and Brookings report significant 'speed bumps' in enterprise scaling.
The ROI Gap
Companies begin reporting stalled productivity gains despite high AI spend.
Enterprise Pilot Phase
Fortune 500 companies begin wide-scale internal testing of AI assistants.
The Agentic Shift
Focus moves from simple text generation to autonomous AI agents.
Enterprise Pilot Phase
Major SaaS providers integrate 'Copilot' style features into core products.
Enterprise Integration
Major software vendors (Microsoft, Google, Salesforce) embed AI across all core products.
Phase 3 Trials
Large-scale multi-site trials aim to provide definitive data for regulatory approval.
Generative AI Hype
Massive VC inflows into foundational model developers like OpenAI and Anthropic.
Generative Hype
Initial surge in consumer AI interest following ChatGPT launch.
GenAI Emergence
Launch of ChatGPT triggers global corporate interest in generative AI.
SAP Expansion
Canada amends the Special Access Program to include restricted psychedelic substances.
Regulatory Shift
Health Canada begins granting Section 56 exemptions for terminally ill patients.
Foundational Research
Johns Hopkins and NYU publish landmark studies on psilocybin for cancer-related distress.
The AIPI poll revealing 68% voter support for AI model review introduces new risk for early-stage AI companies: potential delays, compliance costs, and investor caution. However, startups building safety-by-design into their products may differentiate themselves as regulatory-safe bets.
Source: 800wvhu.iheart.com · veropatriot.iheart.com
New research from Gallup, Brookings Metro, and Johns Hopkins reveals a surge in professional AI usage, even as organizations hit significant implementation hurdles. While individual productivity is climbing, companies are struggling with 'shadow AI' and the technical debt of legacy infrastructure.
A comprehensive study by Gallup, Brookings Metro, and Johns Hopkins reveals that while AI usage is rising across the digital economy, structural 'speed bumps' are slowing enterprise-wide integration. The findings highlight a critical gap between tool availability and organizational readiness, signaling a shift in the venture landscape toward AI governance and training.
A joint report from Gallup, Brookings Metro, and Johns Hopkins reveals that while AI usage is rising, organizations are hitting significant 'speed bumps' in full-scale adoption. The research highlights a growing gap between tool availability and the human infrastructure required to support it.
Source: weartv.com · kimatv.com
A landmark study has demonstrated that a single dose of psilocybin, paired with psychological support, significantly outperforms traditional nicotine replacement therapies for long-term smoking cessation. The findings suggest a paradigm shift in treating substance use disorders through psychedelic-assisted therapy.
Emerging clinical research indicates that psilocybin-assisted therapy can significantly alleviate existential dread and depression in terminally ill patients. This development marks a potential paradigm shift in palliative care, moving beyond physical pain management to address deep-seated psychological trauma.
